These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Patel RN; Nigam GB; Jatale RG; Desai D; Makharia G; Ahuja V; Limdi JK Indian J Gastroenterol; 2020 Apr; 39(2):176-185. PubMed ID: 32483692 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Papamichael K; Cheifetz AS Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029 [TBL] [Abstract][Full Text] [Related]
27. Use of anti-TNF drug levels to optimise patient management. Papamichael K; Cheifetz AS Frontline Gastroenterol; 2016 Oct; 7(4):289-300. PubMed ID: 28839870 [TBL] [Abstract][Full Text] [Related]
28. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Gisbert JP; Chaparro M J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929 [TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Marquez-Megias S; Nalda-Molina R; Sanz-Valero J; Más-Serrano P; Diaz-Gonzalez M; Candela-Boix MR; Ramon-Lopez A Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631594 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR; Digestion; 2020; 101(6):683-691. PubMed ID: 31461706 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Vande Casteele N; Feagan BG; Wolf DC; Pop A; Yassine M; Horst SN; Ritter TE; Sandborn WJ Inflamm Bowel Dis; 2021 Jul; 27(8):1346-1355. PubMed ID: 33051647 [TBL] [Abstract][Full Text] [Related]
32. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Kapoor A; Crowley E Front Pediatr; 2021; 9():661536. PubMed ID: 34123968 [TBL] [Abstract][Full Text] [Related]
33. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Samaan MA; Arkir Z; Ahmad T; Irving PM Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466 [TBL] [Abstract][Full Text] [Related]
34. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074 [TBL] [Abstract][Full Text] [Related]
35. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958 [TBL] [Abstract][Full Text] [Related]
36. Is Therapeutic Drug Monitoring for Anti-tumour Necrosis Factor Agents in Adults With Inflammatory Bowel Disease Ready for Standard of Care? A Systematic Review and Meta-analysis. Shah R; Hoffman GR; El-Dallal M; Goldowsky AM; Chen Y; Feuerstein JD J Crohns Colitis; 2020 Sep; 14(8):1057-1065. PubMed ID: 32064510 [TBL] [Abstract][Full Text] [Related]
37. Management Decisions in Crohn's Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels. Wu Y; Wen A; Selvanderan SP; Xuan W; Andrews JM; Koo JH; Williams AJ; Ng W; Connor S Crohns Colitis 360; 2021 Jul; 3(3):otab042. PubMed ID: 36776656 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. Lee SD; Shivashankar R; Quirk D; Zhang H; Telliez JB; Andrews J; Marren A; Mukherjee A; Loftus EV J Clin Gastroenterol; 2021 Mar; 55(3):195-206. PubMed ID: 32740098 [TBL] [Abstract][Full Text] [Related]
39. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort. Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623 [TBL] [Abstract][Full Text] [Related]
40. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. Irving PM; Gecse KB Gastroenterology; 2022 Apr; 162(5):1512-1524. PubMed ID: 35167865 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]